Mycobacterium Infection
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Mycobacterium infection is an early-stage landscape with 10 programs across 7 companies. The most active players are Horizon Therapeutics Ireland DAC, Otsuka, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 6 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Horizon Therapeutics Ireland DAC
1 program
Otsuka
1 program
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2 programs
Pfizer
1 program
Viatris Specialty LLC
1 program
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
1 program
Pipeline
Programs by Phase
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)